)
Edge31 Oct 2025
Rolls-Royce: Full Thrust Ahead
From century-old crafted perfection to pandemic shock and reset, Rolls-Royce's story is shaped by heritage, turbulence, and a disciplined climb back.
Arcturus Therapeutics (ARCT) investor relations material
Arcturus Therapeutics Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary10 Nov, 2025
Executive summary
Interim phase 2 data for ARCT-032 (mRNA therapy for cystic fibrosis) showed safety and mucus plug reduction in class one CF adults, supporting further development and expanded trial design.
ARCT-810 (mRNA therapy for OTC deficiency) is progressing toward regulatory meetings in H1 2026 to discuss pivotal trial strategy for both pediatric and adult populations.
COVID-19 vaccine (Costave/KOSTAIVE) commercialized in Japan; US BLA filing delayed indefinitely due to FDA regulatory changes, with commercial progress continuing in Asia and Europe.
Next-gen pandemic flu vaccine (ARCT-2304) showed robust immune response and favorable safety in phase 1, with federal funding received for development.
Additional cost reductions are planned in Q4 2025 to further extend the cash runway.
Financial highlights
Q3 2025 revenue was $17.2M, down $24.5M year-over-year, primarily due to reduced CSL collaboration revenue; nine-month revenue was $74.8M, down $54.7M.
Q3 operating expenses were $33.7M, down from $52.4M last year; nine-month operating expenses were $119.8M, down from $191.8M.
Q3 R&D expenses were $23.3M, down from $39.1M; Q3 G&A expenses were $10.4M, down from $13.3M.
Q3 net loss was $13.5M ($0.49/share), compared to $6.9M ($0.26/share) last year; weighted-average shares outstanding were 27.2M.
Cash, cash equivalents, and restricted cash totaled $237.3M as of September 30, 2025.
Outlook and guidance
Cash runway extended into 2028 due to cost reductions and delayed CF phase 3 trial commencement until 2027.
12-week CF study for ARCT-032 to begin in H1 2026; regulatory meetings for ARCT-810 planned for H1 2026.
Continued support from CSL is anticipated for KOSTAIVE commercialization in Asia and Europe.
General and administrative expenses are expected to decrease slightly over the next twelve months.
Additional details on Costave commercialization and cost reduction to be provided in March year-end call.
What endpoints drive ARCT-032's Phase III decision?
ARCT-810: OTC adult vs. pediatric trial strategy
Primary factors extending cash runway into 2028
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Arcturus Therapeutics earnings date
Q4 20255 Mar, 2026
Next Arcturus Therapeutics earnings date
Q4 20255 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Arcturus Therapeutics Holdings Inc. is a biotechnology company focused on developing RNA-based therapeutics for the treatment of infectious diseases, rare diseases, and other medical conditions. The company utilizes its proprietary self-amplifying mRNA technology and lipid nanoparticle delivery system to develop vaccines and therapies. Arcturus' pipeline includes treatments for diseases such as COVID-19 and other RNA-based therapies targeting unmet medical needs. The company is headquartered in San Diego, California, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage